Use of botulinum toxin for rosacea: a pilot study

Introduction: Rosacea is a chronic inflammatory skin disease. The intradermal application of botulinum toxin (BT) has been studied as a therapeutic option for patients who struggle to manage flushing and/or persistent facial erythema. There is no standard protocol for BT application in rosacea....

Full description

Bibliographic Details
Main Authors: Jaqueline Barbeito de Vasconcellos, Isabele Oliveira Santos, Daniela Alves Pereira Antelo
Format: Article
Language:English
Published: Sociedade Brasileira de Dermatologia (SBD) 2021-12-01
Series:Surgical & Cosmetic Dermatology
Subjects:
Online Access:http://www.surgicalcosmetic.org.br/Content/imagebank/pdf/v13/en_v13a19.pdf
Description
Summary:Introduction: Rosacea is a chronic inflammatory skin disease. The intradermal application of botulinum toxin (BT) has been studied as a therapeutic option for patients who struggle to manage flushing and/or persistent facial erythema. There is no standard protocol for BT application in rosacea. Objective: To evaluate the effectiveness of botulinum toxin application on erythematotelan-giectatic rosacea. Methods: Pilot study with case series. We applied intradermal BT in 10 patients with a diagnosis of rosacea and symptoms of persistent erythema and/or facial flushing. Patients received 10 to 15 injections per hemiface (1 unit of onabotulinum BT per injection) and 0 to 5 injections in the nasal region, totaling 25 to 35 units per patient. Results: Seventy-five percent of the patients presented a reduction in flush and erythema intensity. The follow-up time was three months, and no serious adverse events were observed. Conclusions: The therapeutic arsenal to control erythema and facial flushing of rosacea, especially refractory to the usual treatment, should consider the intradermal application of BT type A.
ISSN:1984-8773